ResoTher Pharma is a clinical-stage biotechnology company based in Copenhagen, Denmark, focused on developing innovative peptide-based drugs aimed at addressing inflammation, particularly in the context of cardiovascular diseases. Their lead compound, RTP-026, is designed to mimic the action of the endogenous protein Annexin A1, which plays a crucial role in the resolution of inflammation and tissue protection. By targeting innate immune cells, RTP-026 aims to modulate the inflammatory response during the recovery phase of myocardial infarction, thereby reducing the risk of reinfarction and other major cardiovascular events. The company is currently advancing RTP-026 through clinical trials, with a Phase 2a study set to begin in 2024.

The mechanism of action for RTP-026 involves regulating the recruitment of neutrophils and monocytes to injured tissues, promoting the apoptosis of neutrophils to limit tissue damage, and facilitating the removal of apoptotic cells through efferocytosis. This orchestrated response not only aids in the resolution of inflammation but also activates cellular events that support tissue healing. ResoTher Pharma's commitment to addressing unmet needs in cardiovascular care is underscored by their focus on developing potent immune modulators with excellent safety profiles, as demonstrated in previous clinical studies. The company actively seeks collaborations to further advance their resolution therapies and improve patient outcomes in critical care settings.

Denmark

ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on discovering and developing novel peptide-based drugs to treat neutrophil-driven inflammation (resolution therapy). ResoTher Pharma has received a grant from the European Innovation Council (EIC) to support a phase 2a clinical study of their lead candidate RTP-026 for myocardial infarction.

ResoTher Pharma

Company Details